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Objective. To evaluate the frequency and type of vascular lesions and to study the association of factor V gene G1691A
(Leiden) and prothrombin gene G20210A polymorphisms with venous thrombosis in Italian patients with Behc¸et’s disease
(BD).
Methods. Included were 118 consecutive Italian BD patients followed over a 3-year period (1997–1999) who satisfied the
International Study Group criteria for BD. The control group consisted of 132 healthy Italian blood donors. All BD
patients and controls were genotyped by polymerase chain reaction and allele-specific restriction enzyme techniques for
factor V Leiden and prothrombin gene G20210A polymorphisms.
Results. Vascular lesions were observed in 37 (31.4%) patients. The 2 most common lesions were subcutaneous
thrombophlebitis (10.2%) and deep vein thrombosis (DVT) of the legs (22.8%). No significant demographic and clinical
differences between patients with and without DVT were present. The distribution of allele and genotype frequencies of
prothrombin gene G20210A and factor V Leiden polymorphisms did not differ significantly between BD patients and
healthy controls. The frequencies of carriage rates of prothrombin gene G20210A and factor V Leiden polymorphisms in
BD patients with and without DVT were similar. However, the frequency of 20210A allele was significantly higher in BD
patients with ocular disease than in those without, particularly in the patients with posterior uveitis/retinal vasculitis.
Conclusions. The frequency and types of vascular lesions in Italian BD patients were similar to those reported in studies
from other countries. No association between factor V Leiden mutation and G20210A mutation in the 3!-untranslated
region of the prothrombin gene with DVT was found. However, a prothrombin gene G20210A mutation may influence the
development and severity of ocular involvement in BD.
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INTRODUCTION
Behc¸et’s disease (BD) is a multisystemic inflammatory dis-
ease of unknown origin characterized by recurrent oral
aphtous ulcers, genital ulcers, uveitis, and skin lesions
(1,2). Vasculitis is the pathologic lesion common to most
of the clinical manifestations of BD. Vascular lesions, al-
though not included in the diagnostic criteria for BD by the
International Study Group (3), are detected in 10–30% of
patients (4). Superficial thrombophlebitis and involve-
ment of the deep veins of the extremities are the most
common vascular lesions.
The pathogenesis of thrombosis in BD is unknown, al-
though the contribution of multiple factors is likely. Var-
ious abnormalities related to endothelial cell functions
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have been described in BD (4–9). Endothelial dysfunction
resulting from vasculitis could play an important role in
the pathogenesis of thrombotic manifestations observed in
BD. However, thrombophilia may also play a key role. The
factor V Leiden mutation is the most common cause of
inherited thrombophilia. A single point mutation 1691G to
A in the factor V gene produces a 506Arg to Gln replace-
ment in the cleavage site of the factor V moiety, making it
resistant to degradation by activated protein C. This mu-
tation increases the risk of venous thrombosis (10–12). An
odds ratio (OR) for venous thrombosis of 6.2 was estimated
for factor V Leiden carriers in a large random sample of the
Italian population (13). Discordant data have been re-
ported on the association between deep vein thrombosis
(DVT) and factor V Leiden mutation in BD (14–20).
A second mutation that is an established inherited cause
of thrombophilia is the G20210A mutation in the 3!-un-
translated region of the prothrombin gene. This mutation
is reported to increase the risk of venous thrombosis by
almost 3-fold (21). The 20210A allele is associated with
elevated prothrombin levels, itself a risk factor of throm-
bosis (22). Interestingly, its geographic distribution paral-
lels the prevalence of BD, the highest prevalence being
found in southern Europe and the Middle East (23), where
the prevalence of BD is higher. The association between
this mutation and venous thrombosis in BD has been stud-
ied in Turkish and Spanish patients, with discordant data
being reported (15,20,24).
The aim of this study was to determine whether or not
these 2 mutations were associated with an increased risk
of venous thrombosis in Italian patients with BD. We also
evaluated the frequency and the types of vascular lesions
in our series of Italian patients.
PATIENTS AND METHODS
Patients. Participants were consecutive BD patients fol-
lowed at the Rheumatology, Ophthalmology, and Neurol-
ogy Units in hospitals in Bologna, Ferrara, Milano, Pal-
ermo, Potenza, Prato, Reggio Emilia, and Trento during a
3-year period (1997–1999) who satisfied the International
Study Group criteria for BD (3). Of the 125 patients that
were recruited, 7 were excluded because they were of
northern African or Turkish origin. The 118 patients that
were white, of Italian descent, and residing in Italy for at
least 1 generation were the cohort of patients studied. The
control group consisted of 132 white people of Italian
descent who were unrelated blood donor volunteers. No
ethnic differences were present between patients and con-
trols, and none were of Jewish background. The study was
approved by the Ethics Committees of the participating
centers and informed consent was obtained from patients
and controls before inclusion in the study.
The diagnosis of DVT and subcutaneous thrombophle-
bitis was based on clinical data and confirmed by ultra-
sonography or contrast venography.
HLA class I typing. Serologic HLA class I typing was
performed by the standard microlymphocytotoxicity tech-
nique, using peripheral blood lymphocytes. Of the 118
Italian patients with BD, 94 were typed for HLA–B51. The
control group was made up of 130 Italian healthy subjects.
Polymerase chain reaction (PCR) analysis of prothrom-
bin gene G20210A mutation and factor V gene G1691A
mutation. Blood for molecular biology analysis was
drawn by venipuncture of the antecubital vein in triso-
dium citrate (129 mmol/liter) 1:9 vol:vol and DNA was
extracted with InstaGene whole blood kit (Bio-Rad, Her-
cules, CA) on fresh or frozen whole blood samples. PCR
was performed with AmpliTaq polymerase on a 9600
Thermal Cycler, both from Perkin Elmer (Emeryville, CA),
using specific in-house synthesised primers.
For prothrombin gene G20210A, the primers were TCT
AGA AAC AGT TGC CTG GC (forward) and ATA GCA
CTG GGA GCA TTG AA*GC (reverse), where * indicates a
primer specific for the mutated allele. The amplification
mixture was as follows: dNTPs 200 mM, forward primer 20
pmole, reverse primer 20 pmole, buffer 1", Taq DNA
polymerase 1.5 U, DNA 10 !l, distilled water 50 !l. Am-
plification procedure was as follows: first 2 minutes at
94°C, then 30 seconds at 94°C, 30 seconds at 60°C, and 40
seconds at 72°C for 35 cycles, and finally 5 minutes at
72°C. The restriction enzyme digestion mixture was as
follows: Hinf I restriction endonuclease 1 U, buffer 1",
bovine serum albumin 2 mg, amplified DNA 17 !l; the
mixture was incubated for 2 hours at 37°C.
Electrophoresis was performed on a 4% agarose gel for 1
hour at 85 volts (25).
For factor V Leiden gene G1691A mutation, the primers
were GGA ACA ACA CCA TGA TCA GAG CA (forward)
and TAG CCA GGA GAC CTA ACA TGT TC (reverse). The
amplification mixture was as follows: dNTPs 200 mM,
forward primer 20 pmole, reverse primer 20 pmole, buffer
1", Taq DNA polymerase 1.5 U, DNA 10 !l, distilled
water 50 !l. Amplification procedure was as follows: first
2 minutes at 94°C, then 30 seconds at 94°C, 30 seconds at
60°C, and 40 seconds at 72°C for 35 cycles, and finally 5
minutes at 72°C.
The restriction enzyme digestion mixture was as fol-
lows: Mnl I restriction endonuclease 1 U, buffer 1", bo-
vine serum albumin 2 mg, amplified DNA 17 !l; the mix-
ture was incubated for 2 hours at 37°C.
Electrophoresis was performed on a 3% agarose gel for
45 minutes at 85 volts (22).
Statistical analysis. Statistical analysis was done using
SPSS statistical package (SPSS, Chicago, IL). The frequen-
cies of the alleles and genotypes among the case patients
and control groups were determined and were compared
by the chi-square test and Fischer’s exact probability tests.
ORs and their 95% confidence intervals (95% CIs) were
calculated. ORs were estimated by the method of Haldane
if required. Differences between groups for continuous
variables were evaluated by Student’s t-test.
RESULTS
Table 1 shows the clinical and demographic characteris-
tics of 118 Italian patients with BD. We observed 37
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(31.4%) patients with vascular lesions. The 2 most com-
mon lesions were subcutaneous thrombophlebitis (12/118,
10.2%) and DVT of the legs (25/118, 21.2%). Two patients
had isolated intracardiac thrombosis and 1 patient had
associated Budd-Chiari syndrome and extensive inferior
vena cava and leg vein thromboses. Therefore, a total of 27
patients had evidence of DVT. Arterial lesions were not
present. There were no significant differences between
patients with and without DVT (Table 1).
The allele and genotype frequencies of prothrombin
gene G20210A and factor V gene G1691A polymorphisms
in BD patients and in the control group are shown in Table
2. The distributions did not differ significantly between
BD patients and healthy controls.
The comparisons of the frequencies of carriage rates of
prothrombin gene G20210A and factor V gene G1691A
polymorphisms in controls and in BD patients with and
without DVT are shown in Table 3. No significant differ-
ences were found. No patient was carrying both factor V
Leiden and prothrombin gene G20210A mutations.
The HLA–B51 allele frequency was significantly higher
in BD patients compared with healthy controls (57.4%
versus 19.2%; P # 0.0001, OR 5.7, 95% CI 3.1–10.3). We
also investigated possible associations of the 2 polymor-
Table 1. Demographic and clinical features of 118 Italian patients with Behc¸et’s disease*
Total BD
(n ! 118)
BD without DVT
(n ! 91)
BD with DVT
(n ! 27)
Female/male 54/64 (45.8./54.2) 41/50 (45.1/54.9) 13/14 (48.1/51.9)
Age at disease onset, mean $ SD, years 30 $ 12 29 $ 11 31 $ 16
Disease duration, mean $ SD, years 12 $ 8 12 $ 8 12 $ 10
Oral ulcer 118 (100) 91 (100) 27 (100)
Genital ulcer 72 (61.0) 59 (64.8) 13 (48.1)
Cutaneous lesions 98 (83.1) 75 (82.4) 23 (85.2)
Erythema nodosum 49 (41.5) 37 (40.7) 12 (44.4)
Papulopustular lesions 67 (56.8) 51 (56.0) 16 (59.2)
Eye lesions 74 (64.4) 56 (61.5) 20 (74.1)
Anterior uveitis† 31 (26.3) 26 (28.6) 5 (18.5)
Posterior uveitis/retinal vasculitis 61 (51.7) 44 (48.4) 17 (63.0)
Arthritis 52 (44.1) 39 (42.9) 13 (48.1)
Subcutaneous thrombophlebitis 12 (10.2) 10 (11.0) 2 (7.4)
Central nervous system involvement 24 (20.3) 20 (22.0) 4 (14.8)
Epididymitis 6 (5.1) 5 (5.5) 1 (3.7)
Positive pathergy test result‡ 26 (49.0) 17 (48.6) 9 (50.0)
HLA–B51§ 54 (57.4) 41 (55.4) 13 (65.0)
* Data presented as number (%) unless otherwise noted. BD # Behc¸et’s disease; DVT # deep vein thrombosis.
† Sixteen of 31 patients had isolated anterior uveitis.
‡ Pathergy test was performed in 53 patients (35 without DVT and 18 with DVT).
§ HLA typing was performed in 94 patients (74 without DVT and 20 with DVT)
Table 2. Allele and genotype frequencies of prothrombin gene G20210A and factor V gene G1691A polymorphisms in Italian
Behc¸et’s disease patients and controls*
Variable
Healthy controls
(n ! 132)
Behc¸et’s disease
(n ! 118) P
Odds ratio
(95% CI)
Factor V G1691A
Alleles
A 5/264 (1.9) 9/236 (3.8) NS 1.4 (0.9–2.0)
G 259/264 (98.1) 227/236 (96.2) 0.7 (0.3–1.4)
Genotypes
AA 0/132 0/118
GA 5/132 (3.8) 9/118 (7.6) NS
GG 127/132 (96.2) 109/118 (92.4)
Prothrombin G20210A†
Alleles
A 5/264 (1.9) 8/234 (3.4) NS 1.3 (0.8–2.0)
G 259/264 (98.1) 226/234 (96.6) 0.7 (0.4–1.4)
Genotypes
AA 0/132 0/117
GA 5/132 (3.8) 8/117 (6.8) NS
GG 127/132 (96.2) 109/117 (93.2)
* Data presented as number with variable/total number possible (%). 95% CI # 95% confidence interval; NS # not significant.
† Prothrombin gene G20210A polymorphism test was performed on 117 of 118 patients with Behc¸et’s disease.
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phisms studied with BD with or without DVT stratifying
on HLA–B51. Although this analysis was limited by the
low number of patients studied, no significant associations
were observed in HLA–B51-positive or HLA–B51-negative
patients (data not shown).
The associations between prothrombin gene G20210A
and factor V gene G1691A polymorphisms and BD clinical
manifestations defined in Table 1 were evaluated in the
118 BD Italian patients comparing patients with and with-
out manifestations. The frequency of 20210A allele was
significantly higher in BD patients with ocular disease
than in those without (10.8% versus 0%; P # 0.03, OR
11.4, 95% CI 5.2–24.9), particularly in the patients with
posterior uveitis/retinal vasculitis (13.1% versus 0%; P #
0.004, OR 18.2, 95% CI 8.3–39.8).
DISCUSSION
We observed a 31.4% prevalence of vascular lesions in our
consecutive series of Italian patients with BD. This fre-
quency is similar to that reported in other studies. In
particular, Koc¸ et al, in a study designed to evaluate the
prevalence of vascular involvement in BD, showed a prev-
alence of 27.7% in a series of Turkish patients (4). The 2
most common lesions observed in our study were subcu-
taneous thrombophlebitis and DVT of the legs. Two pa-
tients had isolated intracardiac thrombosis and 1 patient
had associated hepatic vein thrombosis and extensive in-
ferior vena cava and leg vein thromboses. Similar to the
experience cited by Bayraktar et al (26), this patient had a
catastrophic course with death occurring a few months
after the development of vascular lesions. Arterial lesions
were not present in our series of Italian patients.
We also compared the demographic and clinical char-
acteristics of the patients with and without DVT. No sig-
nificant differences were found. Koc¸ et al reported a sta-
tistically significantly higher frequency of pathergy
positivity, erythema nodosum, and eye involvement in
patients with vascular lesions (4). Eye lesions, in particu-
lar posterior uveitis/retinal vasculitis, were also more fre-
quent in our Italian patients with DVT, although the dif-
ference was not significant.
The factor V Leiden mutation is the most common cause
of inherited thrombophilia (12). Seven studies have eval-
uated factor V Leiden as a potential risk factor for DVT in
BD patients (14–20) (Table 4). Three studies have exam-
ined Turkish patients (14–16), 1 study examined patients
from Saudi Arabia (17), 1 studied Palestinian and Jordan
patients (18), and 2 studies examined European patients
(19,20). The results were controversial. Two of the studies
reported a significant association between factor V Leiden
mutation and venous thrombosis in BD (14,17), but in the
4 other studies this association was not confirmed (15,18–
20). The seventh study was limited by the low number of
patients with DVT (only 5) (16). Two of the studies were
well-planned, case-control studies that evaluated 2 series
of Turkish patients with BD referred to Ankara and Istan-
bul Universities (14,15). Their results were conflicting. Gu¨l
et al (14) showed that heterozigosity for factor V gene
mutation was associated with an almost 6-fold increase in
the risk of venous thrombosis, whereas Toydemı`r et al (15)
showed that this mutation was not a risk factor for venous
thrombosis in BD.
In our study, we did not find any association between
factor V Leiden mutation and venous thrombosis in Italian
patients with BD. Similarly, the factor V gene mutation
was not found in 2 series of BD patients with thrombosis,
1 from France (15 patients), the other from Spain (14
patients) (19,20). Therefore, the factor V Leiden mutation
seems not to be a risk factor for venous thrombosis in
European patients with BD.
Toydemı`r et al (15) found a high frequency of factor V
Leiden mutation in BD patients without DVT and sug-
gested an association between this mutation and BD. In
our study, the frequencies of factor V Leiden mutation in
the total BD patients and in the subgroup without DVT
were similar to that of controls.
Another study established inherited cause of thrombo-
philia is the G20210A mutation in the 3!-untranslated
region of the prothrombin gene (21). We described 2 cases
of BD with thrombotic lesions that were heterozygous for
the prothrombin G20210A mutation (27). We thus decided
to plan the present study to confirm a possible association.
We did not find any significant differences in the fre-
quency of prothrombin gene mutation between Italian BD
patients with and without DVT. A recent study from
Spain, confirming our results, did not find any association
between this mutation and thrombosis (prevalently DVT)
in patients with BD (Table 4) (20). Discordant data are
reported on Turkish BD patients. A heterozygous pro-
thrombin gene G20210A mutation was found to be signif-
icantly associated with DVT by Gu¨l et al (24); this was not
Table 3. Comparisons of carriage rates of prothrombin gene G20210A and factor V gene G1691A polymorphisms in controls
and Italian Behc¸et’s disease patients with and without deep vein thrombosis*
Carriage rate
BD with DVT
(n ! 27) A
BD without DVT
(n ! 91) B
Control
(N ! 132) C
A versus C
P
B versus C
P
A versus B
P
Factor V G1691A
A 1 (3.7) 8 (8.8) 5 (3.8) NS NS NS
G 26 (96.3) 83 (91.2) 127 (96.2)
Prothrombin G20210A†
A 2 (7.4) 6 (6.7) 5 (3.8) NS NS NS
G 25 (92.6) 84 (93.3) 127 (96.2)
* Data presented as number (%). BD # Behc¸et’s disease; DVT # deep vein thrombosis; NS # not significant.
† Prothrombin gene G20210A polymorphism test was performed on 117 of 118 patients with Behc¸et’s disease.
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the case in the Toydemı`r et al study (15). In these 2 Turk-
ish studies, there were large differences in the prevalence
of this mutation in BD patients with and without DVT
(31.3% versus 3.3%).
There are different possible explanations for the con-
flicting results regarding the association of these 2 throm-
bophilic mutations with BD; allelic heterogeneity existing
between ethnic groups, modification of the association by
other genetic or environmental factors that vary between
the populations studied, selection bias in sampling of
cases or controls, and publication bias. However, one of
the most important causes of failure to replicate findings in
genetic association studies is the inadequacy of sample
sizes (28). So far, the maximum number of patients with
DVT studied has been only 32. To test the association
between thrombophilic gene polymorphisms and DVT in
BD, a larger group of cases with DVT would be needed.
Therefore, multicenter collaborations to recruit an ade-
quate number of cases are required.
In our study, we also evaluated whether prothrombin
gene G20210A and factor V gene G1691A polymorphisms
were associated with specific clinical findings comparing
patients with and without certain manifestations. The fre-
quency of the 20210A allele was significantly higher in BD
patients with ocular disease than in those without. These
data suggest that a prothrombin gene G20210A mutation is
a risk factor for the development of ocular disease. How-
ever, because the strength of the association was higher in
BD patients with more severe ocular disease (posterior
uveitis/retinal vasculitis), this polymorphism may also in-
fluence the severity of ocular involvement. Additional
studies are needed to replicate the association between
gene G20210Amutation and ocular disease. Recurrent vas-
cular occlusion due to an obliterative retinal vasculitis and
vascular thrombosis is a major cause of visual loss in BD.
A prothrombotic condition may be implicated in the
pathogenesis of ocular inflammatory disease in BD.
Verity et al (18) found a significant association between
factor V Leiden mutation and retinal vascular occlusion in
BD (Table 4). However, the strength of the association was
weak (OR 1.06) and the significance was lost upon com-
parison of ocular patients with and without vasoocclusive
disease. We failed to find any association between this
polymorphism and ocular lesions.
In conclusion, our study shows a frequency of vascular
lesions in Italian BD patients similar to that reported in
studies from other countries. However, we did not find any
association between venous thrombosis and the factor V
Leiden mutation or the G20210A mutation in the 3!-un-
translated region of the prothrombin gene. Thrombotic
lesions in Italian BD patients seem more probably related
to the endothelial activation induced by the vasculitic
process. Furthermore, our data support the hypothesis that
prothrombin gene G20210A mutation may influence the
development and severity of ocular involvement in BD.
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